scispace - formally typeset
J

Julia Sacher

Researcher at Max Planck Society

Publications -  83
Citations -  3853

Julia Sacher is an academic researcher from Max Planck Society. The author has contributed to research in topics: Escitalopram & Medicine. The author has an hindex of 28, co-authored 74 publications receiving 3074 citations. Previous affiliations of Julia Sacher include Centre for Addiction and Mental Health & Leipzig University.

Papers
More filters
Journal ArticleDOI

Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods

TL;DR: How physiologically occurring hormonal transition periods in humans can be used to model how changes in sex hormones influence functional connectivity, neurotransmission and brain structure in vivo is discussed.
Journal ArticleDOI

Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorder

TL;DR: The regions identified could serve as a specific region-of-interest-for-disease template for both individual in vivo imaging studies and postmortem histopathologic exploration.
Journal ArticleDOI

Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder

TL;DR: The lower 5-HT1A binding in the amygdala and mesiofrontal areas of SAD patients is consistent with preclinical findings of elevated anxiety, and corroborating the potential validity of 5- HT1A receptors as targets in the treatment of human anxiety disorders.
Journal ArticleDOI

Sexual dimorphism in the human brain: evidence from neuroimaging.

TL;DR: Functional MRI findings from the literature are complemented by the own meta-analysis of fMRI studies on sex-specific differences in human emotional processing to provide a quantitative approach to mapping the consistency of neural networks involved in emotional processing across studies.
Journal ArticleDOI

Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence.

TL;DR: Elevated MAO-A binding after SSRI treatment indicates persistence of a monoamine-lowering process not present in health, and provides a strong conceptual rationale for continuing SSri treatment during early remission.